Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights
Summary
PINNEBERG, Germany--(BUSINESS WIRE)--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. ActivCell Group AG is active in the development and manufacture of cold plasma therapy pens and has received approval for its products (CE-Notified-Body-No. The purchase price for the 100% takeover of ActivCell Group AG is expected to be in the mid-single-digit million-euro range. The closing of the transaction is subject to a final agreement with the shareholders of ActivCell Group AG.